Related references
Note: Only part of the references are listed.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Platelet reactivity in stable cardiovascular patients with chronic kidney disease
Thomas A. Mavrakanas et al.
PLATELETS (2018)
Clash of Oral P2Y12 Receptor Inhibitors in Acute Coronary Syndromes
Yiannis S. Chatzizisis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Carlo Patrono et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting
Tullio Palmerini et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease
Juan-Jesus Carrero et al.
KIDNEY INTERNATIONAL (2017)
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
Francesco Costa et al.
LANCET (2017)
State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives
Giuseppe Gargiulo et al.
EUROINTERVENTION (2017)
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study
Eric A. Secemsky et al.
JAMA CARDIOLOGY (2017)
Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial
Giuseppe Gargiulo et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2017)
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis
Yung-Tai Chen et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials
Jacob A. Udell et al.
EUROPEAN HEART JOURNAL (2016)
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial
Giulia Magnani et al.
EUROPEAN HEART JOURNAL (2016)
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial
Gerard Helft et al.
EUROPEAN HEART JOURNAL (2016)
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study
Ian T. Meredith et al.
CIRCULATION (2016)
Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent Randomized Substudy of the I-LOVE-IT 2 Trial
Yaling Han et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2016)
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation The IVUS-XPL Randomized Clinical Trial
Sung-Jin Hong et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2016)
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention
Robert W. Yeh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents Risk Scores From PARIS
Usman Baber et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
Glenn N. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
The Risk of Major Hemorrhage with CKD
Amber O. Molnar et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction
Marc P. Bonaca et al.
JAMA CARDIOLOGY (2016)
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting
Stefanie Schulz-Schuepke et al.
EUROPEAN HEART JOURNAL (2015)
6-Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin The Randomized, Multicenter ITALIC Trial
Martine Gilard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Gennaro Giustino et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials
Tullio Palmerini et al.
LANCET (2015)
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Eliano Pio Navarese et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Eliano Pio Navarese et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Randomized, Controlled Trial
Cheol Whan Lee et al.
CIRCULATION (2014)
Second-Generation Drug-Eluting Stent Implantation Followed by 6-Versus 12-Month Dual Antiplatelet Therapy The SECURITY Randomized Clinical Trial
Antonio Colombo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial
Jean-Philippe Collet et al.
LANCET (2014)
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Laura Mauri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Ron T. Gansevoort et al.
LANCET (2013)
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis
Eliano P. Navarese et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease A Systematic Review and Meta-analysis
Suetonia C. Palmer et al.
ANNALS OF INTERNAL MEDICINE (2012)
Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study
Hyeon-Cheol Gwon et al.
CIRCULATION (2012)
Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting A Randomized Multicenter Trial
Marco Valgimigli et al.
CIRCULATION (2012)
A New Strategy for Discontinuation of Dual Antiplatelet Therapy The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
Byeong-Keuk Kim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Ticagrelor in the Renal Dysfunction Subgroup: Subjugated or Substantiated?
Gilles Montalescot et al.
CIRCULATION (2010)
Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Stefan James et al.
CIRCULATION (2010)
Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy
Anand Singla et al.
AMERICAN HEART JOURNAL (2009)
Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial)
Arijit Dasgupta et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel
Lawrence Ang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Share Paper
